NKGen Biotech, Inc. (NKGN)
OTCMKTS
· Delayed Price · Currency is USD
0.0600
0.00 (0.00%)
Apr 29, 2026, 11:30 AM EST
NKGen Biotech Employees
NKGen Biotech had 26 employees as of December 31, 2024. The number of employees decreased by 37 or -58.73% compared to the previous year.
Employees
26
Change (1Y)
-37
Growth (1Y)
-58.73%
Revenue / Employee
n/a
Profits / Employee
-$905,923
Market Cap
7.84M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26 | -37 | -58.73% |
| Dec 31, 2023 | 63 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Galera Therapeutics | 3 |
| Synlogic | 1 |
| Brainstorm Cell Therapeutics | 20 |
| Orgenesis | 77 |
| Mosaic ImmunoEngineering | 8 |
NKGen Biotech News
- 20 days ago - NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - GlobeNewsWire
- 5 weeks ago - NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™ - GlobeNewsWire
- 7 weeks ago - NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026 - GlobeNewsWire
- 3 months ago - NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. - GlobeNewsWire
- 7 months ago - NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market - GlobeNewsWire
- 7 months ago - NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology - GlobeNewsWire
- 7 months ago - NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum - GlobeNewsWire
- 8 months ago - NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - GlobeNewsWire